This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the recent FDA approval of Lilly's EBGLYSS (lebrikizumab-lbkz) for Moderate-to-Severe Atopic Dermatitis.
Ticker(s): LLYWho's the expert?
- Treats 15 patients per month with plaque psoriasis
- Reviewed the literature regarding the phase 2b data of NDI-034858
Interview Goalto discuss the recent FDA approval of Lilly's EBGLYSS (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
